Patents by Inventor Megan Baldwin

Megan Baldwin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100239568
    Abstract: Methods for the treatment of cancer with combination therapies that include anti-VEGF antibodies are provided. Methods for diagnosing resistant tumors are also provided.
    Type: Application
    Filed: April 28, 2010
    Publication date: September 23, 2010
    Applicant: GENENTECH, INC.
    Inventors: Farbod SHOJAEI, Cuiling Zhong, Megan Baldwin, Hans-Peter Gerber, Napoleone Ferrara
  • Publication number: 20080206243
    Abstract: Provided are methods of treating kidney disorders in a subject by administering an effective amount of VEGFR agonist, e.g., a Flt1 agonist to a subject. The agonists are composed of compositions comprising VEGFR agonists, e.g., VEGF, antibodies directed to Flt1, Flt1 ligands, Flt1 small molecule activators, or Flt1 selective agents in a pharmaceutically acceptable carrier for use in activating Flt1.
    Type: Application
    Filed: April 25, 2008
    Publication date: August 28, 2008
    Applicant: Genentech, Inc.
    Inventors: Megan Baldwin, Hans-Peter Gerber, Napoleone Ferrara
  • Publication number: 20070264193
    Abstract: Methods for the treatment of cancer with combination therapies that include anti-VEGF antibodies are provided. Methods for diagnosing resistant tumors are also provided.
    Type: Application
    Filed: March 28, 2007
    Publication date: November 15, 2007
    Applicant: Genentech, Inc.
    Inventors: Farbod Shojaei, Cuiling Zhong, Megan Baldwin, Hans-Peter Gerber, Napoleone Ferrara
  • Publication number: 20070264259
    Abstract: Provided are methods of treating kidney disorders in a subject by administering an effective amount of VEGFR agonist, e.g., a Flt1 agonist to a subject. The agonists are composed of compositions comprising VEGFR agonists, e.g., VEGF, antibodies directed to Flt1, Flt1 ligands, Flt1 small molecule activators, or Flt1 selective agents in a pharmaceutically acceptable carrier for use in activating Flt1.
    Type: Application
    Filed: March 26, 2007
    Publication date: November 15, 2007
    Applicant: Genentech, Inc.
    Inventors: Megan Baldwin, Hans-Peter Gerber, Napoleone Ferrara
  • Publication number: 20070250941
    Abstract: Transgenic non-human animals and methods of producing non-human transgenic animals comprising within their genome a conditional targeted mutation in a VEGFR, e.g., VEGFR1 or VEGFR2, gene are provided along with methods and vectors used to produce such animals or cells.
    Type: Application
    Filed: March 26, 2007
    Publication date: October 25, 2007
    Applicant: Genentech, Inc.
    Inventors: Megan Baldwin, Hans-Peter Gerber, Napoleone Ferrara
  • Publication number: 20050282228
    Abstract: Methods for activating endothelial growth factors VEGF-C or VEGF-D with plasmin, and methods of treatment comprising administering a phamarceutical compositions comprising plasmin. Also disclosed are methods for screening for inhibitors of activation of the growth factors by plasmin, and method of treatment by blocking activation of VEGF-C/D activation by plasmin. Further disclosed are methods for screening for other proteases that activate VEGF-C/D, and for inhibitors of such activation. The invention further includes inhibitors of plasmin activity and methods of treating patients in need thereof with said inhibitors.
    Type: Application
    Filed: July 21, 2003
    Publication date: December 22, 2005
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Bradley Mccoll, Megan Baldwin, Steven Stacker, Narc Achen